- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
What’s New in the Medicine Chest: Hailey-Hailey Disease
Key Takeaways
- Hailey-Hailey disease is a genetic disorder causing painful skin blistering, impacting patients' quality of life, especially in severe cases.
- A case study highlighted a patient with severe Hailey-Hailey disease who improved with dupilumab, a monoclonal antibody for atopic dermatitis.
Del Rosso outlined new and off-label therapies for the disease that he shared in his presentation at Winter Clinical Miami.
In a recent interview with Dermatology Times, James Del Rosso, DO, a dermatologist based in Las Vegas, Nevada, shared insights on Hailey-Hailey disease he shared during his presentation at Winter Clinical Miami titled, “What’s New in the Medicine Chest?” Known for his extensive work in clinical dermatology, research, and educational initiatives, Del Rosso provided valuable information about this rare and challenging skin condition.
Hailey-Hailey disease, or benign familial pemphigus, is a genetic disorder that presents painful blistering and crusting of the skin. The condition can significantly impact a patient’s quality of life, particularly when it becomes widespread or severe.
Del Rosso referenced a compelling case study reported by David Altman’s group in Michigan, which detailed a patient with diffuse Hailey-Hailey disease. This patient experienced severe involvement, including behind 1 knee, leading to immobility and complications such as venous thrombosis. The case highlights the profound physical and functional challenges associated with the disease.
The patient, who had been unresponsive to conventional therapies, demonstrated remarkable improvement with dupilumab, a monoclonal antibody initially approved for atopic dermatitis. While the patient did not have atopic dermatitis, dupilumab proved effective in managing their Hailey-Hailey disease, underscoring its potential as a therapeutic option for refractory cases.
This case, along with detailed clinical photographs, has been accepted for publication in the Journal of Clinical and Aesthetic Dermatology. Del Rosso emphasized the significance of this development, as it showcases an innovative treatment avenue for a condition that remains difficult to manage. The forthcoming publication will provide additional insights for clinicians seeking effective interventions for Hailey-Hailey disease.
To read and listen to more of our conference coverage, click here.
Click here for more insights from Del Rosso, including the full interview with Dermatology Times on his presentation at Winter Clinical 2025.
